Secukinumab

Secukinumab falls under the category of biologic medications, exerting its therapeutic action by specifically targeting interleukin-17A (IL-17A), a pivotal protein in the body implicated in the inflammatory cascade driving psoriasis. IL-17A, a cytokine of significance in the pathogenesis of psoriasis, orchestrates inflammation and fosters the generation of various cytokines and immune cells that actively contribute to the disease's progression. By impeding IL-17A, Secukinumab effectively mitigates inflammation, decelerates the proliferation of skin cells, and ameliorates the symptomatic manifestations of psoriasis. This multifaceted action aids in alleviating the symptoms associated with the condition.